These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 872292)

  • 21. Antithrombin III, heparin cofactor and antifactor Xa in a clinical material.
    Odegård OR; Teien AN
    Thromb Res; 1976 Feb; 8(2):173-8. PubMed ID: 56054
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma.
    Ofosu FA; Choay J; Anvari N; Smith LM; Blajchman MA
    Eur J Biochem; 1990 Oct; 193(2):485-93. PubMed ID: 2226466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombin III. Theory and clinical applications. H. P. Smith Memorial Lecture.
    Seegers WH
    Am J Clin Pathol; 1978 Apr; 69(4):299-359. PubMed ID: 347919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proceedings: The relationship between antithrombin III, progressive antithrombin activity and anti Xa activity in plasma.
    Whigham K; Howie PW; Forbes CD; Prentice CR
    Thromb Diath Haemorrh; 1975 Sep; 34(1):365. PubMed ID: 52904
    [No Abstract]   [Full Text] [Related]  

  • 25. Interaction of factor Xa with heparin does not contribute to the inhibition of factor Xa by antithrombin III-heparin.
    Owen BA; Owen WG
    Biochemistry; 1990 Oct; 29(40):9412-7. PubMed ID: 2248954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of heparin on the neutralization of factor Xa and thrombin by the plasma alpha-2-globulin inhibitor.
    Yin ET
    Thromb Diath Haemorrh; 1975 Feb; 33(1):43-50. PubMed ID: 47195
    [No Abstract]   [Full Text] [Related]  

  • 27. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
    Tran TH; Bondeli C; Marbet GA; Duckert F
    Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a pentosan polysulphate upon thrombin and factor Xa inactivation by antithrombin III.
    Scully MF; Kakkar VV
    Biochem J; 1984 Sep; 222(3):571-8. PubMed ID: 6207810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The activated factor X-antithrombin III reaction rate: a measure of the increased thrombotic tendency induced by estrogen-containing oral contraceptives in rabbits.
    Gitel SN; Stephenson RC; Wessler S
    Haemostasis; 1978; 7(1):10-8. PubMed ID: 640489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides.
    Barrowcliffe TW; Havercroft SJ; Kemball-Cook G; Lindahl U
    Biochem J; 1987 Apr; 243(1):31-7. PubMed ID: 3606581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel antithrombin-heparin covalent complex: antithrombotic and bleeding studies in rabbits.
    Chan AK; Berry L; Klement P; Julian J; Mitchell L; Weitz J; Hirsh J; Andrew M
    Blood Coagul Fibrinolysis; 1998 Oct; 9(7):587-95. PubMed ID: 9863706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor Xa inactivation by a heparinized hydrogel.
    Rollason G; Sefton MV
    Thromb Res; 1986 Nov; 44(4):517-25. PubMed ID: 3798412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anti-heparin properties of human low-density lipoprotein.
    MacGregor IR; Lane DA; Kakkar VV
    Biochim Biophys Acta; 1980 Mar; 617(3):472-9. PubMed ID: 7189413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
    Sandler RM; Liebman HA; Patch MJ; Teitelbaum A; Levine AM; Feinstein DI
    Cancer; 1982 Nov; 50(10):2106-10. PubMed ID: 6957257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of antithrombin III on the activity of the coagulation factors VII, IX and X.
    Osterud B; Miller-Andersson M; Abildgaard U; Prydz H
    Thromb Haemost; 1976 Apr; 35(2):295-304. PubMed ID: 61631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antithrombin III, heparin cofactor and antifactor Xa in relation to age, sex and pathological condition.
    Panicucci F; Sagripanti A; Conte B; Pinori E; Vispi M; Lecchini L
    Haemostasis; 1980; 9(5):297-302. PubMed ID: 7409613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of rat factors X and Xa: demonstration of factor Xa in rat plasma.
    Enjyoji K; Miyazaki K; Kato H
    J Biochem; 1991 Jun; 109(6):890-8. PubMed ID: 1718949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The acceleration of the inhibition of platelet prothrombinase complex by heparin.
    Ellis V; Scully MF; Kakkar VV
    Biochem J; 1986 Jan; 233(1):161-5. PubMed ID: 3954724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.